cariboubio.comHealthcareFounded: 2011Funding to Date: $41.55MM
Caribou Biosciences is a leading clinical-stage CRISPR genome editing biotechnology company developing an internal pipeline of off-the-shelf, genome-edited CAR-T and natural killer (NK) cell therapies.
For more details on financing and valuation for Caribou Biosciences, register or login.
View Enterprise Value for Caribou Biosciences.
To read this article and more news on Caribou Biosciences, register or login.